Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Liabilities and Shareholders Equity (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $163.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 8.2% year-over-year to $163.6 million, compared with a TTM value of $545.2 million through Sep 2025, down 15.89%, and an annual FY2024 reading of $146.4 million, down 0.55% over the prior year.
  • Liabilities and Shareholders Equity was $163.6 million for Q3 2025 at X4 Pharmaceuticals, up from $105.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $210.6 million in Q2 2024 and bottomed at $81.0 million in Q2 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $139.7 million, with a median of $141.7 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity soared 114.02% in 2023, then plummeted 50.07% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $117.2 million in 2021, then surged by 32.78% to $155.6 million in 2022, then fell by 5.35% to $147.3 million in 2023, then fell by 0.55% to $146.4 million in 2024, then grew by 11.68% to $163.6 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for XFOR at $163.6 million in Q3 2025, $105.2 million in Q2 2025, and $130.0 million in Q1 2025.